Literature DB >> 24642356

Exercise-mimicking treatment fails to increase Fndc5 mRNA & irisin secretion in primary human myotubes.

Timea Kurdiova1, Miroslav Balaz1, Alexander Mayer2, Denisa Maderova1, Vitazoslav Belan3, Christian Wolfrum4, Jozef Ukropec1, Barbara Ukropcova5.   

Abstract

Irisin, myokine secreted by skeletal muscle, was suggested to mediate some of exercise health benefits via "browning" of white adipose tissue. However, mounting evidence contradicts the regulatory role of exercise for muscle irisin production/secretion in humans. Thus, we explored the direct effect of exercise-mimicking treatment on irisin in human primary muscle cells in vitro. Human primary muscle cell cultures were established from lean, obese prediabetic and type-2-diabetic individuals. Complex metabolic phenotyping included assessment of insulin sensitivity (euglycemic hyperinsulinemic clamp) and adiposity content&amp;distribution (MRI&amp;MRS). In vitro exercise-mimicking treatment (forskolin+ionomycin) was delivered in 1-h pulse/day during differentiation. Fndc5 mRNA (qRT-PCR) and secreted irisin (ELISA) were determined in cells and media. Exercise-mimicking treatment more than doubled Pgc1α mRNA in differentiated muscle cells. Nevertheless, Fndc5 mRNA was reduced by 18% and irisin in media by 20%. Moreover, Fncd5 mRNA was increased in myotubes derived from individuals with type-2-diabetes, independent on exercise-mimicking treatment. Fndc5 mRNA in cells was positively related to fasting glycemia (p=0.0001) and negatively to whole-body insulin sensitivity (p<0.05). Collectively, our data do not support the role of exercise-related signaling pathways in irisin regulation in human skeletal muscle and confirm our previous observations on increased Fndc5 expression in muscle cells from individuals with type-2-diabetes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Exercise-mimicking treatment; Fndc5; Human myotubes; Irisin; Myokines; Type 2 diabetes

Mesh:

Substances:

Year:  2014        PMID: 24642356     DOI: 10.1016/j.peptides.2014.03.003

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  16 in total

Review 1.  In vitro experimental models for examining the skeletal muscle cell biology of exercise: the possibilities, challenges and future developments.

Authors:  Steven Carter; Thomas P J Solomon
Journal:  Pflugers Arch       Date:  2018-10-05       Impact factor: 3.657

Review 2.  Physiology and role of irisin in glucose homeostasis.

Authors:  Nikolaos Perakakis; Georgios A Triantafyllou; José Manuel Fernández-Real; Joo Young Huh; Kyung Hee Park; Jochen Seufert; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2017-02-17       Impact factor: 43.330

3.  Circulating irisin levels and muscle FNDC5 mRNA expression are independent of IL-15 levels in mice.

Authors:  LeBris S Quinn; Barbara G Anderson; Jennifer D Conner; Tami Wolden-Hanson
Journal:  Endocrine       Date:  2015-04-29       Impact factor: 3.633

4.  PGC-1 mediates the regulation of metformin in muscle irisin expression and function.

Authors:  Zaigang Yang; Xu Chen; Yujuan Chen; Qian Zhao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

5.  Myricanol modulates skeletal muscle-adipose tissue crosstalk to alleviate high-fat diet-induced obesity and insulin resistance.

Authors:  Shengnan Shen; Qiwen Liao; Tian Zhang; Ruile Pan; Ligen Lin
Journal:  Br J Pharmacol       Date:  2019-10-14       Impact factor: 8.739

6.  Impact of supervised exercise training on pulmonary function parameters, exercise capacity and Irisin Biomarker in Interstitial lung disease patients.

Authors:  Rahma Mohammad Alyami; Abdulrahman Mohammed Alhowikan; Abdullah Rashed Alharbi; Ghada Al-Nafisah
Journal:  Pak J Med Sci       Date:  2020 Jul-Aug       Impact factor: 1.088

Review 7.  Irisin and Myonectin Regulation in the Insulin Resistant Muscle: Implications to Adipose Tissue: Muscle Crosstalk.

Authors:  Luis Gamas; Paulo Matafome; Raquel Seiça
Journal:  J Diabetes Res       Date:  2015-05-05       Impact factor: 4.011

8.  Circulating Irisin Is Reduced in Male Patients with Type 1 and Type 2 Myotonic Dystrophies.

Authors:  Elena Dozio; Elena Passeri; Rosanna Cardani; Stefano Benedini; Carmen Aresta; Rea Valaperta; Massimiliano Corsi Romanelli; Giovanni Meola; Valeria Sansone; Sabrina Corbetta
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-14       Impact factor: 5.555

9.  Muscle-dependent regulation of adipose tissue function in long-lived growth hormone-mutant mice.

Authors:  Xinna Li; Jacquelyn A Frazier; Edward Spahiu; Madaline McPherson; Richard A Miller
Journal:  Aging (Albany NY)       Date:  2020-05-28       Impact factor: 5.682

Review 10.  Irisin: A Hope in Understanding and Managing Obesity and Metabolic Syndrome.

Authors:  Lidia I Arhire; Laura Mihalache; Mihai Covasa
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.